Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response

Table 1 The primers and probes used for the low density lipoprotein receptor genes

	exon 8 (c.1171G > A)	F5'-CTACAAGTGCCAGTGTGAGGAA-3'
		R5’_CCCACCACTCTGCTTGTAAGGCGTGAGGCCGCC-3'
		Allele 1 specific probe VIC-ACACGAAGGCCTGC-NFQ
LDLR primers		Allele 2 specific probe 6-FAM-ACACGAAGACCT GC-NFQ
	exon 10 (c.1413G > A)	F5'- CGGCGTCTCTTCCTATGACA-3'
		R5'- GTCCAGTAGATGTTGCTGTGGAT-3'
		Allele 1 specific probe VIC-ATCAGCAGGGAC ATC-NFQ
		Allele 2 specific probe 6-FAM-TCAGCAGAGACA TC-NFQ

Table 2 The frequency of the genotypes of gene polymorphisms in the studied groups n (%)

	Non responders (n = 301)	Responders (n = 356)	Control(n = 160)	P value
LDR exon8 c.1171G>A				< 0.001
AA	157 (52.2)	13 (3.6)	6 (3.8)
GA	92 (30.6)	54 (15.2)	85 (53.1)
GG	52 (17.2)	289 (81.2)	69 (43.1)
LDR exon10 c.1413G>A				0.204
AA	48 (15.9)	51 (14.3)	15 (9.4)
GA	191 (63.5)	215 (60.4)	109 (68.1)
GG	62 (20.6)	90 (25.3)	36 (22.5)

Table 3 Allele frequency and risk ratio in non-responders vs responders

	Non responders	Responders	P value	OR (95%CI)
	n (%)	n (%)
LDR exon 8 c.1171G>Aallele
A	406 (67.4)	80 (11.2)	< 0.001	16.4 (12.3-21.8)
G	196 (32.6)	632 (88.8)		1
exon 10 c.1413 G>Aallele
A	287 (47.7)	317 (44.5)	0.253	1.13 (0.9-1.4)
G	315 (52.3)	395 (55.5)		1

Table 4 Steatosis and body mass index mean level in different LDLR genotypes in hepatitis C virus patients n (%)

	LDR exon 8 c.1171 G>A			P value	LDR exon 10 c.1413 G>A			P value
	AA	GA	GG		AA	GA	GG
BMI (kg/m2)	28.7 ± 4.7	28.1 ± 4.8	26.6 ± 4.3	< 0.001	27.3 ± 4.3	27.5 ± 4.8	27.4 ± 4.4	0.887
Steatosis
0	64 (37.6)	70 (47.9)	204 (59.8)	< 0.001	50 (50.5)	208 (51.2)	80 (52.6)	0.938
1,2,3	106 (62.4)	76 (52.1)	137 (40.2)		49 (49.5)	198 (48.8)	72 (47.4)